Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with...
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks.
Target Price
The average target price of ADAP is 0.73 and suggests 1230% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell